TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34287493
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment and adjuvant laser therapy
Study: 36215044
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) with medical therapy
Study: 36356037
Drug: 600 IU
Normalized name: Vitamin E 4600 IU/5 ML Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 IU vitamin D3 + 500 mg calcium
Study: 36356037
Drug: 1200 IU
Normalized name: Vitamin E 1200 IU Oral Capsule, Liquid Filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 IU vitamin D3 + 500 mg calcium
Study: 36356037
Drug: 4000 IU
Normalized name: Cholecalciferol 4000 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 IU vitamin D3 + 500 mg calcium
Study: 36356037
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg calcium)
Study: 36435474
Drug: Placebo candy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo candy with 250 mg of flaxseed meal
Study: 34132492
Drug: Empagliflozin (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (pooled doses)
Study: 33143203
Drug: Micronutrient fortified
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micronutrient fortified meal (570 kcal) in the form of a bar and shake containing >75% of the FDA Daily Values for all essential vitamins and minerals
Study: 34362266
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (n = 43)
Study: 36949248
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg
Study: 36337273
Drug: Lycopene (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene (25 mg once a day for 8 weeks)
Study: 35075752
Drug: Ablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative fractional CO2 laser and placebo (plain normal saline solution)
Study: 33248596
Drug: Experimental diets
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental diets with 957 g/kg inclusion of grains (corn, sorghum, wheat, barley)
Study: 36017704
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg/d
Study: 35777931
Drug: Intrafascial injection
Normalized name: CHYMOPAPAIN 2nKatU/ML INTRADISCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrafascial injection
Study: 35777931
Drug: Extrafascial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrafascial injection
Study: 33539971
Drug: Bevacizumab added
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab added to adjuvant chemotherapy
Study: 32951746
Drug: Oak Gall
Normalized name: Rhus chinensis gall extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oak Gall vaginal cream
Study: 32227140
Drug: Long-term exposure
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term exposure to PM2.5 (0.88 μg/m3 increase)
Study: 33159658
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg semaglutide
Study: 33159658
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg semaglutide
Study: 39508144
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine
Study: 33377146
Drug: Price reductions
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Price reductions (e.g., coupons)
Study: 34354179
Drug: rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20 mg QD
Study: 34354179
Drug: simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 40 mg combined with ezetimibe 10 mg QD
Study: 33713522
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT) using Hair Growth System (TOPHAT655) for 20 minutes, two sessions per week for 16 weeks (total of 32 treatments).
Study: 37254209
Drug: Combination antibiotic
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antibiotic therapy
Study: 32932881
Drug: Plant Milking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant Milking Technology applied to Morus alba L. (mulberry tree)
Study: 35444013
Drug: Dostarlimab as
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dostarlimab as maintenance therapy after chemoradiation
Study: 34836020
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (HMB and HP)
Study: 38065202
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy
Study: 35638576
Drug: Multidisciplinary rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary rehabilitation therapy using mobile applications
Study: 38807685
Drug: TAU (Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU (Treatment as Usual)
Study: 32180164
Drug: Tiotropium 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 5 µg
Study: 33529723
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (OIT) with raw egg white powder, maintenance dose of 1 g of egg white protein for 8 months
Study: 34013444
Drug: Long-term prophylactic
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term prophylactic intravenous antibiotics (14 days)
Study: 32400342
Drug: Praziquantel mass
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel mass drug administration
Study: 34284351
Drug: Caffeine 4
Normalized name: caffeine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 4 mg/kg
Study: 33542479
Drug: Blinatumomab (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab (9 μg/day cycle 1 week 1, 28 μg/day thereafter for 4 weeks)
Study: 34269121
Drug: tPA administration
Normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tPA administration
Study: 34773995
Drug: Low concentration
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentration popliteal-sciatic nerve block (SNB) with 0.125% bupivacaine [20 ml] and dexamethasone [5 mg]
Study: 34962979
Drug: Edoxaban 30/15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 30/15 mg
Study: 34788550
Drug: Green Tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green Tea Extract (GTE) 400 mg every 12 hours for 3 months
Study: 39663378
Drug: Seltorexant 20
Normalized name: Seltorexant
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seltorexant 20 mg
Study: 35588970
Drug: Rapid phenotypic
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid phenotypic antibiotic susceptibility testing (AST) with antimicrobial stewardship programme (ASP)
Study: 32275366
Drug: Medication (Metformin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Metformin, 500 mg twice a day)
Study: 33361337
Drug: Triplet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triplet therapy (pembrolizumab 200 mg IV every 3 weeks + dabrafenib 150 mg orally twice daily + trametinib 2 mg orally once daily)
Study: 32034789
Drug: Ca(OH)2 +
Normalized name: IMMUNOGLOBULIN G (HUMAN-MOUSE MONOCLONAL CA2 HEAVY CHAIN ANTI-HUMAN TUMOR NECROSIS FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL CA2 LIGHT CHAIN, DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca(OH)2 + Ibuprofen
Study: 36046011
Drug: Ultrasound-guided right-sided
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided right-sided stellate ganglion block with 6 ml 0.25% ropivacaine
Study: 32052503
Drug: PEG‐IFN monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN monotherapy and PEG‐IFN and lamivudine
Study: 32052503
Drug: HBV RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV RNA level above 5.5 log c/mL at week 12
Study: 35835531
Drug: Laparoscopic ovarian
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic ovarian cystectomy (gold standard treatment)
Study: 39142758
Drug: Drug-coated balloons
Normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-coated balloons (DCBs)
Study: 34547623
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet with 200 mg/kg LYC
Study: 34547623
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet with 100 �g/kg AFB1
Study: 33032328
Drug: Medications
Normalized name: AUTONOMIC MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications
Study: 35958679
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg lidocaine
Study: 36270754
Drug: Extended-release injectable
Normalized name: Exenatide for Extended-Release Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release injectable buprenorphine (BUP-XR)
Study: 36270754
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine (BUP-SL)
Study: 35986418
Drug: Oral liquid
Normalized name: ACAI ORAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liquid methadone (MET)
Study: 34812466
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of freeze-dried strawberry powder (FDSP)
Study: 34812466
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g FDSP + 25 g of placebo powder
Study: 35002810
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment group (n = 28)
Study: 32538267
Drug: Inert pill
Normalized name: inert ingredients Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert pill
Study: 37023858
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine
Study: 33356406
Drug: Implantable cardioverter-defibrillator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardioverter-defibrillator (ICD) therapy
Study: 35940831
Drug: PEN-FAST score-guided
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEN-FAST score-guided management with direct oral penicillin challenge
Study: 35940831
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (skin testing followed by oral penicillin challenge if skin testing is negative)
Study: 33187543
Drug: XBYRT (Traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: XBYRT (Traditional Chinese Medicine herbal decoction)
Study: 32356007
Drug: TXA 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA 250 mg once daily
Study: 32356007
Drug: TXA 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA 500 mg twice daily
Study: 33307277
Drug: Tiotropium added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium added to inhaled corticosteroids and long-acting beta-agonists
Study: 35608433
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine (0.5 mg/kg) combined with Dezocine (0.1 mg/kg)
Study: 33637066
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine and bupivacaine (ITMB)
Study: 34717968
Drug: 5% menthol
Normalized name: MENTHOL 5 g TOPICAL PATCH [Cold Hot Medicated Patch 5% Menthol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% menthol gel (Biofreeze™)
Study: 34329606
Drug: Vincristine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine (1.5 mg/m2) plus dexamethasone (6 mg/m2 per day for 7 days) during the second year of treatment (Control group)
Study: 38252440
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline infusion)
Study: 35805620
Drug: 2.4 g
Normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g per day WNS
Study: 35805620
Drug: 4.8 g
Normalized name: ALCOHOL 74.8 g in 100 g TOPICAL SWAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.8 g per day WNS
Study: 35627475
Drug: L-citrulline supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-citrulline supplementation
Study: 33736915
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of measles-mumps-rubella and one dose of varicella vaccine
Study: 33736915
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of measles-mumps-rubella-varicella vaccine
Study: 34606114
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (two doses of measles-mumps-rubella vaccine)
Study: 33736915
Drug: Both one-dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both one-dose and two-dose varicella-containing vaccines
Study: 33736915
Drug: Increasing varicella-specific
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing varicella-specific antibody concentrations
Study: 34518906
Drug: Peritonsillar injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritonsillar injection of bupivacaine (0.1 mg/kg)
Study: 34518906
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (12.5 mg/kg)
Study: 34518906
Drug: Peritonsillar injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritonsillar injection of bupivacaine
Study: 39049802
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment
Study: 32877581
Drug: Intensive lifestyle
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive lifestyle intervention (weekly sessions for 6 months, monthly sessions for 18 months)
Study: 32279451
Drug: Liraglutide (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (0.9 mg/day)
Study: 35366488
Drug: Pet therapy
Normalized name: Pet Pectillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pet therapy program
Study: 34343424
Drug: Roflumilast 500
Normalized name: ROFLUMILAST 500MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 500 µg once daily for 6 months
Study: 35180298
Drug: Acetaminophen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (500 mg or 1000 mg every 6 hours for 72 hours)
Study: 35180298
Drug: No acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: No acetaminophen (Control)
Study: 33789574
Drug: Colistin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin treatment duration
Study: 39454998
Drug: Oral CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CPAP
Study: 33727460
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (Group TA)
Study: 34333191
Drug: Lifestyle physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle physical activity intervention (asthma education, Fitbit, monthly group sessions, text messages, individual step goals, and study manual)
Study: 35061236
Drug: DS-1040 (0.6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-1040 (0.6, 1.2, 2.4 or 4.8 mg)
Study: 36107497
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (rESWT)
Study: 32682361
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy (US)
Study: 35446596
Drug: Semisolid gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semisolid gel (GEL)
Study: 33764613
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of plasma gel combined with fractional CO2 laser
Study: 33963943
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine (CHX) solution
Study: 36383760
Drug: Professional oral
Normalized name: Dentek Professional Oral Care Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional oral care
Study: 35753838
Drug: Separate administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administration of MR vaccine
Study: 35753838
Drug: Separate administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administration of EV71 vaccine
Study: 37072361
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate once-monthly (PP1M)
Study: 33972248
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral dose (10 mg/kg)
Study: 33972248
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral (35 mg/kg)
Study: 33972248
Drug: Intravenous (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (20 mg/kg)
Study: 33142450
Drug: Selenium-enriched earthworm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium-enriched earthworm powder (SEP) 0.5 mg/kg
Study: 33142450
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 mg/kg Se)
Study: 35032350
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ESPB) with 0.4 ml/kg of plain bupivacaine 0.25%
Study: 32244933
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg trans-resveratrol twice daily for 12 months
Study: 34808597
Drug: Vitamin C-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C-enriched collagen (hydrolyzed collagen [HC] + C; 20 g HC + 50 mg vitamin C)
Study: 34808597
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 g maltodextrin)
Study: 32151460
Drug: Erythrocyte-encapsulated asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy
Study: 37353495
Drug: Selective Serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Serotonin Reuptake Inhibitor (SSRI) treatment
Study: 33446422
Drug: Lower-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose edoxaban regimen 30/15 mg (LDER)
Study: 33446422
Drug: Higher-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose edoxaban regimen 60/30 mg (HDER)
Study: 35363563
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day caffeine
Study: 35363563
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day caffeine
Study: 32589613
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT), n=33
Study: 35713753
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy in control arm of RCTs with immune checkpoint inhibitors (ICIs)
Study: 35713753
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy in clinical practice (practice group)
Study: 38558248
Drug: Platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based chemotherapy
Study: 35948408
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric derisomaltose in addition to guideline‐recommended therapy for HFrEF
Study: 33641195
Drug: Add-on melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on melatonin (3 mg/day) with valproate (20 mg/kg in two divided doses)
Study: 33419704
Drug: Low-intensity shockwave
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity shockwave therapy (500 pulses, 0.09 mJ/mm², twice a week for 6 weeks)
Study: 33131308
Drug: Low-intensity shockwave
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity shockwave therapy
Study: 36207389
Drug: Neostigmine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine administration after tracheal intubation (Group N)
Study: 36207389
Drug: Neostigmine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine administration (Group N)
Study: 33775312
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin XR (500 mg daily increased to 1500 mg)
Study: 36377973
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice of covalent BTK inhibitor
Study: 33709661
Drug: Electroacupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture combined with conventional Western medicine
Study: 33302114
Drug: PD-1 inhibitors
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitors
Study: 32618251
Drug: MDA (Mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDA (Mass Drug Administration)